



Division of
TennCare

Health Care
Innovation Initiative



Executive Summary

Cystourethroscopy Episode

Corresponds with DBR and Configuration file V1.1

Updated: January 2, 2020


OVERVIEW OF A CYSTOURETHROSCOPY EPISODE

The cystourethroscopy episode revolves around patients who receive a cystourethroscopy procedure. The trigger event is an outpatient cystourethroscopy procedure. All related care – such as imaging and testing, medications, pathology, surgical and medical procedures – is included in the episode. The quarterback, also called the principal accountable provider or PAP, is the clinician or group performing the cystourethroscopy. The cystourethroscopy episode begins 30 days before the triggering procedure and ends 30 days after discharge.


CAPTURING SOURCES OF VALUE

Providers have multiple opportunities during a cystourethroscopy episode to improve the quality and cost of care. Important sources of value include appropriate imaging and testing, reduction of repeat cystourethrosopies, and selection of the most appropriate setting of care to perform the procedure. Other important sources of value include the choice of appropriate surgical approach and appropriate use of pre-operative imaging and testing.

Illustrative Patient Journey



Potential Sources of Value



ASSIGNING ACCOUNTABILITY

The quarterback of the episode is the specific health care provider deemed to have the greatest accountability for the quality and cost of care for the patient. To state it differently, the quarterback is the provider who has the greatest ability to influence all of the health care delivered in a given episode. For the cystourethroscopy episode, the quarterback is the clinician or group who performed the procedure. The contracting entity or tax identification number of the clinician or group performing the cystourethroscopy will be used to identify the quarterback.

MAKING FAIR COMPARISONS

The episode model is designed to be fair to providers and incentivize best practices without penalizing providers who care for sicker patients. As such, important aspects of the model are:

- Inclusion of only the cost of services and medications that are related to the cystourethroscopy in calculation of episode spend.
- Exclusion of episodes when clinical circumstances create the likelihood that the case will deviate substantially from the typical care path or when claims data is likely to be incomplete.
- Risk adjusting episode spend to account for the cost of more complicated patients.

The cystourethroscopy episode pre-trigger window includes specific imaging and testing, specific medications, specific pathology, and specific surgical and medical procedures. During the trigger window, all services and specific medications are included. The post-trigger window includes care for specific diagnoses, specific anesthesia, specific imaging and testing, specific medications, specific pathology, and specific surgical and medical procedures.

Some exclusions apply to any type of episode, i.e., are not specific to a cystourethroscopy. For example, an episode would be excluded if more than one payer was involved in a single episode of care, if the patient was not continuously insured by the payer during the duration of the episode, or if the patient had a discharge status of 'left against medical advice'. Examples of exclusion criteria specific to the cystourethroscopy episode include patients with active management of urinary and prostate cancer, neuromuscular dysfunction of the bladder, congenital genitourinary malformations. These patients have significantly different clinical courses that the episode does not attempt to risk adjust. Furthermore, there may be some factors with a low prevalence or significance that would make accurate risk adjustment difficult and may be used to exclude patients completely instead of adjusting their costs.

For the purposes of determining a quarterback's cost of each episode of care, the actual reimbursement for the episode will be adjusted to reflect risk factors

captured in recent claims data in order to be fair to providers caring for more complicated patients. Examples of patient factors likely to lead to the risk adjustment of a cystourethroscopy episode include hematuria, lower urinary tract symptoms, cystitis and a history of urinary strictures. Over time, a payer may adjust risk factors based on new data.

MEASURING QUALITY

The episode reimbursement model is designed to reward providers who deliver cost effective care AND who meet certain quality thresholds. A quarterback must meet or exceed all established benchmarks for any quality metric tied to gain sharing in order to be eligible to receive monetary rewards from the episode model. Other quality metrics may be tracked and reported for quality improvement purposes but may not be tied directly to gain sharing.

The quality metrics linked to gain sharing for the cystourethroscopy are:

- **Difference in average MED¹/day:** Average difference in MED/day during the 1-30 days prior to the trigger window and average MED/day during the trigger and 30 days after the trigger window, across valid episodes (lower value indicative of better performance)
- **Related ED visit:** Percentage of valid episodes with a related ED visit during the post-trigger window (lower rate indicative of better performance)
- **Repeat cystourethroscopy:** Percentage of valid episodes with one or more cystourethroscopy during the post-trigger window (lower rate indicative of better performance)

The quality metrics that will be tracked and reported to providers but that are not tied to gain sharing are:

- **Average MED/day during the pre-trigger opioid window:** Average MED/day during the 1-30 days prior to the trigger window, across valid episodes (value not indicative of performance)

¹ MED: morphine equivalent dose

- **Average MED/day during the trigger and post-trigger window:** Average MED/day during the trigger and 30 days after the trigger window, across valid episodes (value not indicative of performance)
- **Complications:** Percentage of valid episodes with complications during the post-trigger window (lower rate indicative of better performance)
- **Opioid naïve prescriptions:** Percentage of valid episodes with no opioid prescriptions up to 60 days before the pre-trigger who received an opioid prescription during the episode (lower rate indicative of better performance)
- **Related follow-up care:** Percentage of valid episodes with related follow-up care during the post-trigger window (higher rate indicative of better performance)
- **Related post-trigger admission:** Percentage of valid episodes with any admission during the post-trigger window (lower rate indicative of better performance)

It is important to note that quality metrics are calculated by each payer on a per quarterback basis across all of a quarterback's episodes covered by that payer. Failure to meet all quality benchmarks tied to gain sharing will render a quarterback ineligible for gain sharing with that payer for the performance period under review.